Mercer International Inc. Announces Conference Call for First Quarter 2025 Results
NEW YORK, April 09, 2025 (GLOBE NEWSWIRE) -- Mercer International (NASDAQ: MERC) will release its first quarter results for the period ending March 31, 2025 on Thursday, May 1, 2025, after the close of the market. Juan Carlos Bueno, President and Chief Executive Officer and Richard Short, Chief Financial Officer and Secretary, will be hosting a conference call on Friday, May 2, 2025, at 10:00 am ET to discuss the results.
The conference call will be available to interested parties live over the Internet through a webcast by clicking on or copying and pasting the following link into their web browser: https://edge.media-server.com/mmc/p/9h647upk
A link to the webcast is also available on the Investor Relations section of the company's webpage. For those unable to participate in the live webcast, a replay of the webcast will be archived and accessible through the same link on the Company's website at https://mercerint.com/investors/events-calendar/.The call can be accessed by dialing one of the following:
USA Local - New York: (646) 307-1963USA & Canada Toll Free: (800) 715-9871Canada - Toronto: (647) 932-3411Germany - Frankfurt: +49 69 589964217Germany - Toll-Free: +49 800 0001007
When prompted by the operator, quote Conference ID 6942637 or Conference Name 'Mercer International's First Quarter 2025 Earnings Call' to ensure you are on the right call.
Mercer International Inc. is a global forest products company with operations in Germany, the United States and Canada with consolidated annual production capacity of 2.1 million tonnes of pulp, 960 million board feet of lumber, 210,000 cubic meters of cross-laminated timber, 45,000 cubic meters of glulam, 17 million pallets and 230,000 metric tonnes of biofuels. For further information, please visit www.mercerint.com.
APPROVED BY:
Juan Carlos BuenoPresident & CEO604-684-1099Richard Short, CPA, CACFO & Secretary604-684-1099
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
CoreWeave's Rally Pauses After BofA Cut
Bank of America cut CoreWeave (NASDAQ:CRWV) to Neutral from Buy, arguing the cloud specialist's valuation already reflects most upside even after boosting its price target to $185 from $76. Shares ticked up 1% in premarket trading as investors weighed BofA analyst Brad Sills's view that while CoreWeave has secured a new hyperscaler customer, expanded its OpenAI agreement and raised debt at attractive rates, it's trading at about 25 CY27e EBIT versus a 16 peer average. Warning! GuruFocus has detected 10 Warning Signs with CRWV. Sills flagged that high capex will drive roughly $21 billion of negative free cash flow through 2027with capex set to hit $46.1 billion and 85% of it debt-fundedmaking continued access to reasonably priced financing critical for execution. BofA's more conservative stance follows CoreWeave's rapid infrastructure build-out to meet surging AI demand, and underscores the tension between growth investing and stretched multiples. Why it matters: If CoreWeave can't convert its elevated capex into sustained cash flow growth, its premium valuation could unwind sharply. Investors will be watching upcoming results in for capex guidance and any signs of cash-flow improvement. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
New Toll Brothers Stonegate Court Model Home Opens in Gilbert, Arizona
Exclusive community offers single-family homes with private amenities in sought-after Gilbert GILBERT, Ariz., June 16, 2025 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation's leading builder of luxury homes, announced the grand opening of its model home at Stonegate Court, an exclusive new gated community featuring just 22 expansive single-story homes on 15,000+ square foot home sites in Gilbert, Arizona. The stunning Markham model home showcases beautiful farmhouse architecture with fresh modern organic interior design and an incredible resort-style backyard. The Toll Brothers model home grand opening event at Stonegate Court will be held on Saturday, June 21 from 11 a.m. to 4 p.m. at 4229 S. Quinn Ave. in Gilbert. 'The newly opened Markham model home exemplifies the exceptional luxury designs that Toll Brothers offers at Stonegate Court, providing home shoppers with a first-hand look at the sophisticated features and finishes that define Toll Brothers homes,' said Bob Flaherty, Group President of Toll Brothers in tucked between a handful of well-established neighborhoods, Stonegate Court's enclave-like setting offers homebuyers an ideal blend of sophisticated living and modern convenience. The community features three, single-level floor plans ranging from 3,466 to 4,126+ square-feet with 3 to 6 bedrooms, 3.5 to 5.5 baths, and 3- to 4-car garages, with a wide array of personalization options including private multi-generational living suites, expansive multi-slide doors, courtyards, wine rooms, exterior fireplaces, and more. Homes are priced starting at $1.38 million. The intimate setting of the community provides a serene escape for residents, while being ideally located within the desirable Higley Unified School District and near major commuter routes and premier shopping, dining, and outdoor recreation. Toll Brothers customers will experience one-stop shopping at the Toll Brothers Design Studio. The state-of-the-art Design Studio allows customers to choose from a wide array of selections to personalize their dream home with the assistance of Toll Brothers professional Design Consultants. For more information on Stonegate Court or other Toll Brothers communities in Arizona, call (844) 836-5263 or visit Toll Brothers Toll Brothers, Inc., a Fortune 500 Company, is the nation's leading builder of luxury homes. The Company was founded 58 years ago in 1967 and became a public company in 1986. Its common stock is listed on the New York Stock Exchange under the symbol 'TOL.' The Company serves first-time, move-up, empty-nester, active-adult, and second-home buyers, as well as urban and suburban renters. Toll Brothers builds in over 60 markets in 24 states: Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Idaho, Indiana, Maryland, Massachusetts, Michigan, Nevada, New Jersey, New York, North Carolina, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Virginia, and Washington, as well as in the District of Columbia. The Company operates its own architectural, engineering, mortgage, title, land development, smart home technology, and landscape subsidiaries. The Company also develops master-planned and golf course communities as well as operates its own lumber distribution, house component assembly, and manufacturing operations. Toll Brothers has been one of Fortune magazine's World's Most Admired Companies™ for 10+ years in a row, and in 2024 the Company's Chairman and CEO Douglas C. Yearley, Jr. was named one of 25 Top CEOs by Barron's magazine. Toll Brothers has also been named Builder of the Year by Builder magazine and is the first two-time recipient of Builder of the Year from Professional Builder magazine. For more information visit From Fortune, ©2025 Fortune Media IP Limited. All rights reserved. Used under license. Contact: Andrea Meck | Toll Brothers, Senior Director, Public Relations & Social Media | 215-938-8169 | ameck@ Photos accompanying this announcement are available at: Sent by Toll Brothers via Regional Globe Newswire (TOLL-REG)Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
Opportunities in the Central Nervous System (CNS) Therapeutics Market: Revenues Forecast to Reach US$156.5 Billion by 2030
Growth is driven by the increasing prevalence of neurological disorders like Alzheimer's, Parkinson's, and schizophrenia, fueled by aging populations and heightened mental health awareness. North America leads the market, with significant growth anticipated in Asia-Pacific due to rising mental health consciousness and improved healthcare access. Central Nervous System Therapeutics Market Dublin, June 16, 2025 (GLOBE NEWSWIRE) -- The "Central Nervous System Therapeutics - Global Strategic Business Report" has been added to global market for Central Nervous System Therapeutics was valued at US$107 Billion in 2024 and is projected to reach US$156.5 Billion by 2030, growing at a CAGR of 6.5% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Central Nervous System Therapeutics market. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as AbbVie Inc., Allergan plc, Anavex Life Sciences Corp., AstraZeneca plc, and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. The global CNS therapeutics market is growing due to increasing disease burden, heightened awareness of mental and neurological health, and the rapid advancement of therapeutic science. Unmet needs across multiple CNS indications, combined with demographic pressures and healthcare digitization, are generating sustained demand for both novel and reformulated therapies. Public and private sector investments in neuroscience research, along with regulatory support for orphan drug development and accelerated pathways, are further incentivizing companies are expanding pipelines through acquisitions, collaborations, and AI-enabled drug discovery platforms focused on CNS targets. At the same time, patient advocacy, digital care models, and personalized treatment paradigms are shifting the industry toward more holistic, outcomes-driven approaches. As complexity in CNS care deepens and precision treatment becomes more attainable, a defining question shapes the market's future: Can CNS therapeutics continue to evolve through biomarker-guided innovation, cross-disciplinary care models, and scalable delivery platforms while addressing the dual challenge of clinical uncertainty and global accessibility?Key Insights: Market Growth: Understand the significant growth trajectory of the Analgesics segment, which is expected to reach US$46.6 Billion by 2030 with a CAGR of a 8.6%. The Anti-Cholinergic Agents segment is also set to grow at 4.6% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $29.2 Billion in 2024, and China, forecasted to grow at an impressive 10.6% CAGR to reach $32.9 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Key Questions Answered: How is the Global Central Nervous System Therapeutics Market expected to evolve by 2030? What are the main drivers and restraints affecting the market? Which market segments will grow the most over the forecast period? How will market shares for different regions and segments change by 2030? Who are the leading players in the market, and what are their prospects? Some of the 44 companies featured in this Central Nervous System Therapeutics market report include: AbbVie Inc. Allergan plc Anavex Life Sciences Corp. AstraZeneca plc Biogen Inc. Bristol Myers Squibb Cipla Limited Dr. Reddy's Laboratories Ltd. Eli Lilly and Company GlaxoSmithKline plc H. Lundbeck A/S Johnson & Johnson Lupin Limited Merck & Co., Inc. Novartis AG Otsuka Pharmaceutical Co., Ltd. Pfizer Inc. Roche Holding AG Takeda Pharmaceutical Company Ltd. Teva Pharmaceutical Industries Ltd. This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include: Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs. Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes historical analysis since 2015. Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends. Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape. Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players. Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities. Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage. Key Attributes Report Attribute Details No. of Pages 395 Forecast Period 2024-2030 Estimated Market Value (USD) in 2024 $107 Billion Forecasted Market Value (USD) by 2030 $156.5 Billion Compound Annual Growth Rate 6.5% Regions Covered Global MARKET OVERVIEW Influencer Market Insights World Market Trajectories Central Nervous System Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E) MARKET TRENDS & DRIVERS Rising Prevalence of Alzheimers, Parkinsons, and Epilepsy Fuels Demand for CNS Drug Innovation Biologics, Gene Therapies, and Small Molecules Converge in Development Pipelines for CNS Disorders Cross-BBB Delivery Technologies and Neurotargeted Carriers Address Long-Standing Bioavailability Barriers Psychiatric Disorders Like Depression and Bipolar Drive Growth in Multimodal CNS Treatment Strategies Digital Therapeutics and CNS Drug Monitoring Tools Expand Clinical Management Capabilities Patient-Centered Outcome Measures Gain Priority in CNS Trial Designs and Payer Decisions High Unmet Need in Rare Neurological Conditions Spurs Orphan Drug Development Activity Aging Demographics and Lifestyle Shifts Expand CNS Therapeutic Demand Across Regions For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Central Nervous System Therapeutics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
